Viropharma Incorporated

Sterling Winthrop Inc.

Microdose Therapeutx, Inc.

Sanofi

Sanofi Sa

Hetero Labs Limited

Wyeth

Other

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Siga Technologies Inc.

Myrexis, Inc.

Kineta Four, LLC

Sanofi Pharmaceuticals, Inc.

Dfh Therapeutics, Inc.

Microdose Therapeutix, Inc.

Theodore John Nitz

Thomas R Bailey

Guy D Diana

David J Aldous

Daniel C Pevear

Christopher J Burns

Thomas A Lessen

David J Rys

Gee-Hong Kuo

Janet A Gaboury

Dorothy C Young

William P Gorczyca

Yijun Deng

Carl Thomas Wild

David Eugene Martin

Sylvie Laquerre

Parthasaradhi Reddy Bandi

Panduranga Reddy Adulla

Rathnakar Reddy Kura

David Krupadanam Gazula Levi

John Swestock

Sylvie Laguerre

Hao Feng

Susan R Rippin

Ashis Kumar Saha

Thomas Faitg

Bhaskar Reddy Kasireddy

Alfred Michael Del Vecchio

Charles W Blackledge

Gerald Rhodes

Martin Seipel

Eswara Rao Bammidi

Torsten Herbertz

Michael Reuman

Jason A Reinhardt

Bheemashankar A Kulkarni

David E Martin

David M Stout

Moussa B H Youdim

Vincent R Zurawski, Jr

Ranga Reddy

Eric O Freed

Edward Glenn

Yanming Zhang

Sudhakar Neela

Tandy D Goldstein

Orly Weinreb

Christian Montalbetti

Yuanming Zhang

Richard Mears

Xinjie Gai

The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the triterpene amine compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C-28 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus-1 (HIV-1).

Triterpene amine derivatives

The present invention relates to C-3 novel triterpenone with C-28 urea derivatives of formula (I); or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, tautomers, stereoisomers, prodrugs, compositions or combination thereof, wherein R, R, R, W, J and X are as defined herein. The present invention also relates to pharmaceutical compositions comprising compounds of formula (I) useful for the treatment of viral diseases and particularly HIV mediated diseases. 

C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors

The invention relates to C-3 novel triterpenone with C-28 amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases (formula 1). 

C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors

The present invention relates to novel betulinic proline imidazole derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases. 

Betulinic proline imidazole derivatives as HIV inhibitors

The present invention concerns novel pharmaceutically active triterpene derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C2-8 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus (HIV).

Extended triterpene derivatives

Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections.

Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever). 

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses

8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective MAO-AB inhibitory activities.

Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof

Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses

The present invention relates to benzofuran derivatives and analogs, as well as compositions containing the same and to the use thereof for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus.

Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases

Growing community of inventors

Pottstown, PA, United States of America

Theodore John Nitz